Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;13(4):39.
doi: 10.21037/atm-25-84. Epub 2025 Aug 26.

Polygenic risk score (PRS) as prostate cancer screening: ready for primetime?

Jinny Park  1 , Jeanny B Aragon-Ching  1
Affiliations
Editorial

Polygenic risk score (PRS) as prostate cancer screening: ready for primetime?

Jinny Park et al. Ann Transl Med. .
No abstract available

Keywords: Prostate cancer; polygenic risk score (PRS); prostate cancer screening; prostate-specific antigen (PSA).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-25-84/coif). J.B.A-C. served as an unpaid Editorial Board Member of Annals of Translational Medicine from June 2023 to May 2025. The other author has no conflicts of interest to declare.

Comment on

  • Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
    McHugh JK, Bancroft EK, Saunders E, Brook MN, McGrowder E, Wakerell S, James D, Rageevakumar R, Benton B, Taylor N, Myhill K, Hogben M, Kinsella N, Sohaib AA, Cahill D, Hazell S, Withey SJ, Mcaddy N, Page EC, Osborne A, Benafif S, Jones AB, Patel D, Huang DY, Kaur K, Russell B, Nicholson R, Croft F, Sobczak J, McNally C, Mutch F, Bennett S, Kingston L, Karlsson Q, Dadaev T, Saya S, Merson S, Wood A, Dennis N, Hussain N, Thwaites A, Hussain S, Rafi I, Ferris M, Kumar P, James ND, Pashayan N, Kote-Jarai Z, Eeles RA; BARCODE1 Steering Committee and Collaborators. McHugh JK, et al. N Engl J Med. 2025 Apr 10;392(14):1406-1417. doi: 10.1056/NEJMoa2407934. N Engl J Med. 2025. PMID: 40214032 Free PMC article.

References

    1. Martin RM, Donovan JL, Turner EL, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA 2018;319:883-95. 10.1001/jama.2018.0154 - DOI - PMC - PubMed
    1. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med 2017;167:449-55. 10.7326/M16-2586 - DOI - PMC - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8. 10.1056/NEJMoa0810084 - DOI - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. 10.1016/S0140-6736(14)60525-0 - DOI - PMC - PubMed
    1. Frånlund M, Månsson M, Godtman RA, et al. Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. J Urol 2022;208:292-300. 10.1097/JU.0000000000002696 - DOI - PMC - PubMed

LinkOut - more resources